A citation-based method for searching scientific literature

Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban, Krzysztof Selmaj, Heinz Wiendl, Cecile Kerloeguen, Roman Willi, Bingbing Li, Algirdas Kakarieka, Davorka Tomic, Alexandra Goodyear, Ratnakar Pingili, Dieter A Häring, Krishnan Ramanathan, Martin Merschhemke, Ludwig Kappos. N Engl J Med 2020
Times Cited: 169







List of co-cited articles
1012 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
861
63

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer,[...]. N Engl J Med 2017
892
33

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, Timothy Vollmer, Jack Antel, Robert J Fox, Amit Bar-Or, Michael Panzara, Neena Sarkar, Sunil Agarwal,[...]. N Engl J Med 2008
32

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Daren J Austin, Jerry M Tolson, Susan A VanMeter, Eric W Lewis, Frederick J Derosier, Monica C Lopez, Sarah T Kavanagh, Aaron E Miller,[...]. Neurology 2018
97
22

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch,[...]. Ann Neurol 2009
604
21

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
21

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
19

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher,[...]. Lancet 2012
795
18

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Chris H Polman, Paul W O'Connor, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, David H Miller, J Theodore Phillips, Fred D Lublin, Gavin Giovannoni, Andrzej Wajgt,[...]. N Engl J Med 2006
17

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg,[...]. Neurology 2016
200
16

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O Khatri, Xavier Montalban, Jean Pelletier, Ruggero Capra, Paolo Gallo, Guillermo Izquierdo,[...]. N Engl J Med 2010
16

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch,[...]. N Engl J Med 2010
542
16

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Amit Bar-Or, Jonathan C Calkwood, Cathy Chognot, Joanna Evershed, Edward J Fox, Ann Herman, Marianna Manfrini, John McNamara, Derrick S Robertson, Daniela Stokmaier,[...]. Neurology 2020
191
15

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or, Peter A J Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J Fox, Michael Panzara,[...]. Ann Neurol 2008
379
15

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner. MAbs 2013
197
15

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Edward Fox, Amy E Lovett-Racke, Matthew Gormley, Yue Liu, Maria Petracca, Sirio Cocozza, Richard Shubin, Sibyl Wray, Michael S Weiss, Jenna A Bosco,[...]. Mult Scler 2021
44
34

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Per S Sorensen, Steen Lisby, Richard Grove, Frederick Derosier, Steve Shackelford, Eva Havrdova, Jelena Drulovic, Massimo Filippi. Neurology 2014
191
14

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner,[...]. Lancet 2012
786
14

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson,[...]. N Engl J Med 2010
14

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Robert J Fox, David H Miller, J Theodore Phillips, Michael Hutchinson, Eva Havrdova, Mariko Kita, Minhua Yang, Kartik Raghupathi, Mark Novas, Marianne T Sweetser,[...]. N Engl J Med 2012
920
14

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Paul O'Connor, Jerry S Wolinsky, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Tomas P Olsson, Hadj Benzerdjeb, Philippe Truffinet, Lin Wang, Aaron Miller,[...]. N Engl J Med 2011
615
14

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz,[...]. Lancet 2018
437
14

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Imtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard. J Comp Eff Res 2020
23
56

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Ludwig Kappos, Robert J Fox, Michel Burcklen, Mark S Freedman, Eva K Havrdová, Brian Hennessy, Reinhard Hohlfeld, Fred Lublin, Xavier Montalban, Carlo Pozzilli,[...]. JAMA Neurol 2021
47
27

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Giancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree,[...]. Lancet Neurol 2019
110
13

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily C Martin, Fernando Dangond, Sana Syed, Jerry S Wolinsky. N Engl J Med 2019
139
12

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Chris H Polman, Stephen C Reingold, Brenda Banwell, Michel Clanet, Jeffrey A Cohen, Massimo Filippi, Kazuo Fujihara, Eva Havrdova, Michael Hutchinson, Ludwig Kappos,[...]. Ann Neurol 2011
12

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
Anna He, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Tim Spelman,[...]. Lancet Neurol 2020
108
12

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
Kjetil Bjornevik, Marianna Cortese, Brian C Healy, Jens Kuhle, Michael J Mina, Yumei Leng, Stephen J Elledge, David W Niebuhr, Ann I Scher, Kassandra L Munger,[...]. Science 2022
266
12

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Roberta Magliozzi, Owain Howell, Abhilash Vora, Barbara Serafini, Richard Nicholas, Maria Puopolo, Richard Reynolds, Francesca Aloisi. Brain 2007
916
11

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson,[...]. JAMA Neurol 2020
240
11

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen,[...]. Lancet 2011
482
11

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Jeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, Amit Bar-Or, Douglas L Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Kubala Havrdová, Bruce A C Cree,[...]. Lancet Neurol 2019
103
11

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Ralf Gold, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Gavin Giovannoni, Krzysztof Selmaj, Carlo Tornatore, Marianne T Sweetser, Minhua Yang, Sarah I Sheikh,[...]. N Engl J Med 2012
11

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Maria P Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Maria Trojano,[...]. Ann Neurol 2021
242
10

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Bruno Brochet, Robert T Naismith, Anthony Traboulsee, Jerry S Wolinsky, Shibeshih Belachew, Harold Koendgen,[...]. Neurology 2020
50
20

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Katharine Harding, Owain Williams, Mark Willis, James Hrastelj, Anthony Rimmer, Fady Joseph, Valentina Tomassini, Mark Wardle, Trevor Pickersgill, Neil Robertson,[...]. JAMA Neurol 2019
108
10

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
J William L Brown, Alasdair Coles, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Trojano, Alessandra Lugaresi,[...]. JAMA 2019
206
10

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Christian Confavreux, Paul O'Connor, Giancarlo Comi, Mark S Freedman, Aaron E Miller, Tomas P Olsson, Jerry S Wolinsky, Teresa Bagulho, Jean-Luc Delhay, Deborah Dukovic,[...]. Lancet Neurol 2014
337
10

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Clare Walton, Rachel King, Lindsay Rechtman, Wendy Kaye, Emmanuelle Leray, Ruth Ann Marrie, Neil Robertson, Nicholas La Rocca, Bernard Uitdehaag, Ingrid van der Mei,[...]. Mult Scler 2020
289
10

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Sokratis A Apostolidis, Mihir Kakara, Mark M Painter, Rishi R Goel, Divij Mathew, Kerry Lenzi, Ayman Rezk, Kristina R Patterson, Diego A Espinoza, Jessy C Kadri,[...]. Nat Med 2021
216
10

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
Stephen L Hauser, Ludwig Kappos, Xavier Montalban, Licinio Craveiro, Cathy Chognot, Richard Hughes, Harold Koendgen, Noemi Pasquarelli, Ashish Pradhan, Kalpesh Prajapati,[...]. Neurology 2021
25
40


Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Giulio Disanto, Christian Barro, Pascal Benkert, Yvonne Naegelin, Sabine Schädelin, Antonella Giardiello, Chiara Zecca, Kaj Blennow, Henrik Zetterberg, David Leppert,[...]. Ann Neurol 2017
558
9

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.
Barbara Serafini, Barbara Rosicarelli, Roberta Magliozzi, Egidio Stigliano, Francesca Aloisi. Brain Pathol 2004
810
9

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.
Ivan Jelcic, Faiez Al Nimer, Jian Wang, Verena Lentsch, Raquel Planas, Ilijas Jelcic, Aleksandar Madjovski, Sabrina Ruhrmann, Wolfgang Faigle, Katrin Frauenknecht,[...]. Cell 2018
227
9

Multiple Sclerosis: Mechanisms and Immunotherapy.
Clare Baecher-Allan, Belinda J Kaskow, Howard L Weiner. Neuron 2018
388
9

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.
Jeffrey M Gelfand, Bruce A C Cree, Stephen L Hauser. Neurotherapeutics 2017
89
10

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Peter A Calabresi, Bernd C Kieseier, Douglas L Arnold, Laura J Balcer, Alexey Boyko, Jean Pelletier, Shifang Liu, Ying Zhu, Ali Seddighzadeh, Serena Hung,[...]. Lancet Neurol 2014
245
9

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Peter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, Douglas Jeffery, Kottil W Rammohan, Anthony T Reder, Timothy Vollmer, Mark A Agius, Ludwig Kappos, Tracy Stites,[...]. Lancet Neurol 2014
562
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.